Matthias Bodenstedt Sells Shares of MoonLake Immunotherapeutics $MLTX
Key Points
- Matthias Bodenstedt sold 39,120 shares of MoonLake Immunotherapeutics ($MLTX) worth $862,204.80.
- $MLTX last traded around $20.13.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Matthias Bodenstedt, Chief Financial Officer at MoonLake Immunotherapeutics ($MLTX), sold 39,120 shares at an average price of $22.04, for a total transaction of $862,204.80. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
MoonLake Immunotherapeutics Stock Up 34.3%
Shares of MoonLake Immunotherapeutics ($MLTX) traded around $20.13 on Wednesday, up 34.3% for the day.
MoonLake Immunotherapeutics Earnings
Analysts Set New Price Targets
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Get MoonLake Immunotherapeutics alerts
New 13F filings, insider trades, and analyst moves on $MLTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.